ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental'

LAKE FOREST, CA / ACCESSWIRE / February 20, 2024 / BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, remains committed to expanding its educational offerings through its web portal, enabling dental clinicians to elevate their standard of dental care and improve patient outcomes through laser technology. "Let's Talk Dental," a free webinar series focused on a variety of topics covering all dental disciplines, kicked off the year with a webinar on January 18, 2024, hosted by Dr. Paul Chang, a periodontist and prosthodontist with a private practice in McKinney, Texas. Dr. Chang lectured on the clinical benefits of using the Waterlase all-tissue dental laser for extractions and immediate implant placement.

The "Let's Talk Dental" webinar includes many relevant and significant topics, such as restorative dentistry, periodontics, endodontics, pediatric dentistry, and dental hygiene. Due to the growing interest in laser dentistry, the series will invite leaders in the industry to share their expertise and educate the general dental public on both all-tissue and soft-tissue laser therapies and related topics. New webinars include:

  • February 15, 2024 and March 5, 2024, when the series will shift its focus to pediatric dentistry topics, starting with a two-part series on frenectomies for infants and adolescents, hosted by Dr. Ben Curtis, a pediatric dentist with a private practice in Canton, TX
  • March 21, 2024, Megan Van Noy, a registered dental hygienist specializing in orofacial myofunctional therapy and owner of NW Myofunctional Therapy, will host a webinar titled "What's Your Tongue Got To Do With It? An Introduction to Myofunctional Therapy."
  • March 28, 2024, "Let's Talk Dental" will wrap up the first quarter of 2024 with a webinar titled "Billing, Coding, and Revenue Tips For Today's Modern Dentist," hosted by renowned author and dental consultant Teresa Duncan.

All webinars will be recorded and uploaded to BIOLASE's education web portal, Education.Biolase.com, which offers tailored education pathways for both all-tissue and soft-tissue lasers through the Waterlase Academy and Epic Diode Academy. The web portal's On-Demand Webinars feature offers a library of recorded webinar content organized by dental categories.

Included on Education.Biolase.com is a list of classroom course offerings, virtual course offerings, clinical animation videos, and case videos.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. As of December 31, 2023, BIOLASE's proprietary laser products incorporate approximately 241 patented and 21 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2023, BIOLASE has sold over 47,700 laser systems in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, those risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:

EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com

SOURCE: BIOLASE, Inc.



View the original press release on accesswire.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.22
+4.06 (1.77%)
AAPL  278.85
+1.30 (0.47%)
AMD  217.53
+3.29 (1.54%)
BAC  53.65
+0.66 (1.25%)
GOOG  320.12
-0.16 (-0.05%)
META  647.95
+14.34 (2.26%)
MSFT  492.01
+6.51 (1.34%)
NVDA  177.00
-3.26 (-1.81%)
ORCL  201.95
-3.01 (-1.47%)
TSLA  430.17
+3.59 (0.84%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.